EMA Strengthens Oversight on Clinical Trials - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

EMA Strengthens Oversight on Clinical Trials

ePT--the Electronic Newsletter of Pharmaceutical Technology

The European Medicines Agency (EMA) has published the final reflection paper concerning ethical and good clinical practice (GCP) aspects of clinical trials. The paper applies to trials conducted outside of the EU and the European Economic Area that are submitted in marketing authorization applications to European regulatory authorities, with the aim of ensuring that all trials, no matter where they’re conducted, meet the required standards.

The framework provided in the paper applies to medicines for humans and enters into force on May 1, 2012.

According to a statement from the EMA, the increasing globalization of pharmaceutical R&D has created a significant challenge for regulators.

“...no matter where you stand today, most clinical trials are being conducted somewhere else in the world, under a different regulatory framework and in a different cultural setting,” explains the EMA statement. “Yet regulators, healthcare professionals and patients worldwide all rely on the same trial data when making decisions on whether to allow a medicine on the market or not and on whether to use a medicine or not.”

The reflection paper addresses this challenge by outlining concrete steps for international cooperation in the regulation of clinical trials, with an emphasis on initiatives that will allow for a common approach to the oversight of trials. In addition, the paper will help assure regulators that ethical and GCP standards are applied to trials, both during development and the marketing authorization application phase.

Clinical trials that are conducted outside of the EU and submitted in marketing authorization applications to European regulatory authorities must meet the same ethical principles and standards that are required of trials performed within EU borders. To achieve this, the paper highlights the importance of independent local ethics committees in the oversight of clinical trials, as well as the necessity of obtaining trial participants’ consent.

The reflection paper follows an extensive public consultation, and has been endorsed by the EMA’s Committee for Medicinal Products for Human Use, the Coordination Group for Mutual Recognition and Decentralized Procedures – Human, the management board of the EMA and the Heads of EU Medicines Agencies.

Related Articles

GSK in Spotlight for Alleged Unethical Trials


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here